Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma

Nat Rev Clin Oncol. 2009 May;6(5):247-8. doi: 10.1038/nrclinonc.2009.50.

Abstract

A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed.

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase III as Topic
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Follow-Up Studies
  • Humans
  • Lenalidomide
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Survival Rate
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Thalidomide
  • Dexamethasone
  • Lenalidomide